CRSP
Price
$46.70
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
4.1B
43 days until earnings call
FATE
Price
$1.04
Change
-$0.06 (-5.45%)
Updated
Jun 27 closing price
Capitalization
119.22M
31 days until earnings call
Interact to see
Advertisement

CRSP vs FATE

Header iconCRSP vs FATE Comparison
Open Charts CRSP vs FATEBanner chart's image
CRISPR Therapeutics AG
Price$46.70
Change-$0.00 (-0.00%)
Volume$32.88K
Capitalization4.1B
Fate Therapeutics
Price$1.04
Change-$0.06 (-5.45%)
Volume$3.75M
Capitalization119.22M
CRSP vs FATE Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. FATE commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Buy and FATE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CRSP: $46.70 vs. FATE: $1.04)
Brand notoriety: CRSP and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 1% vs. FATE: 195%
Market capitalization -- CRSP: $4.1B vs. FATE: $119.22M
CRSP [@Biotechnology] is valued at $4.1B. FATE’s [@Biotechnology] market capitalization is $119.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 6 TA indicator(s) are bullish while FATE’s TA Score has 2 bullish TA indicator(s).

  • CRSP’s TA Score: 6 bullish, 4 bearish.
  • FATE’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than FATE.

Price Growth

CRSP (@Biotechnology) experienced а +5.54% price change this week, while FATE (@Biotechnology) price change was -12.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

FATE is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.1B) has a higher market cap than FATE($119M). CRSP YTD gains are higher at: 18.648 vs. FATE (-36.970). FATE has higher annual earnings (EBITDA): -168.28M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. FATE (240M). FATE has less debt than CRSP: FATE (83.3M) vs CRSP (219M). CRSP has higher revenues than FATE: CRSP (35M) vs FATE (13.3M).
CRSPFATECRSP / FATE
Capitalization4.1B119M3,446%
EBITDA-455.24M-168.28M271%
Gain YTD18.648-36.970-50%
P/E RatioN/AN/A-
Revenue35M13.3M263%
Total Cash1.86B240M773%
Total Debt219M83.3M263%
FUNDAMENTALS RATINGS
CRSP vs FATE: Fundamental Ratings
CRSP
FATE
OUTLOOK RATING
1..100
4068
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
4165
P/E GROWTH RATING
1..100
79100
SEASONALITY SCORE
1..100
42n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (14) in the Biotechnology industry is somewhat better than the same rating for CRSP (67). This means that FATE’s stock grew somewhat faster than CRSP’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that FATE’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as FATE (97). This means that CRSP’s stock grew similarly to FATE’s over the last 12 months.

CRSP's Price Growth Rating (41) in the Biotechnology industry is in the same range as FATE (65). This means that CRSP’s stock grew similarly to FATE’s over the last 12 months.

CRSP's P/E Growth Rating (79) in the Biotechnology industry is in the same range as FATE (100). This means that CRSP’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPFATE
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 18 days ago
84%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ORENF4.450.14
+3.25%
Origin Enterprises PLC
JBHIF66.82N/A
N/A
JB Hi-Fi Limited
ASCBF11.41N/A
N/A
A SPAC II Acquisition Corp.
ANKM3.50N/A
N/A
ANKAM INC.
MTHRY6.88-0.05
-0.65%
M3, Inc.